I learned a new word today…didn’t know that hypogonadism was the official diagnosis, but we all know what it’s for.  There were trials for a similar product for women done by the same company but it failed to work.  BD 

U.S. drug regulators approved a new testosterone gel from BioSante imagePharmaceutical Inc and Teva Pharmaceuticals, a Food and Drug Administration spokeswoman said.

Bio-T-Gel is a topical, once-a-day gel absorbed by the skin to treat low testosterone levels in men, a condition known as hypogonadism.

Shares of the specialty drugmaker BioSante spiked almost 37 percent in after-market trading on Nasdaq to $1.04. Teva shares rose 1.3 percent to $44.10.



Post a Comment